{"id":"W4408405657","doi":"10.1001/jama.2025.1132","title":"Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma","year":2025,"lang":"en","type":"letter","venue":"JAMA","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Nasopharyngeal carcinoma; Internal medicine; Oncology; Clinical endpoint; Adverse effect; Chemoradiotherapy; Adjuvant therapy; Randomized controlled trial; Adjuvant; Survival rate; Surgery; Confidence interval; Radiation therapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001090465,0.0002755614,0.0008922533,0.0001104966,0.0001801508,0.000282107,0.0003500818,0.0003301782,0.001106288],"category_scores_gemma":[0.0008648406,0.0001534904,0.000498524,0.0001517641,0.0003346689,0.0003071434,0.0001661313,0.0006988825,0.0001728037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004408621,"about_ca_system_score_gemma":0.00121939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006259313,"about_ca_topic_score_gemma":0.001857574,"domain_scores_codex":[0.9997635,0.0001138252,0.00002276145,0.00003189839,0.00003808407,0.00002987264],"domain_scores_gemma":[0.9997351,0.00007188929,0.00008089423,0.00002309889,0.00002337635,0.00006568468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2012344,0.01563444,0.05529353,0.004136378,0.00113405,0.0003417601,0.000229808,0.002567656,0.0356814,0.0004258568,0.006153031,0.6771677],"study_design_scores_gemma":[0.3071584,0.4270549,0.1911123,0.001032076,0.004828823,0.0017474,0.0002808104,0.009936992,0.02730078,0.001339196,0.02811802,0.00009016375],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.9840896,0.01307241,0.0003544616,0.000580136,0.0001529909,0.0005933613,0.0001495334,0.00003492886,0.0009725855],"genre_scores_gemma":[0.9946411,0.003463686,0.0006222407,0.0002859629,0.0001347762,0.0003698659,0.000117849,0.000001869031,0.0003626187],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.001106288,"threshold_uncertainty_score":0.005766988,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01954001674613063,"score_gpt":0.2770147039498509,"score_spread":0.2574746872037203,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}